scholarly journals SARS-CoV-2 IgG Antibody and its Clinical Correlates in Convalescent Plasma Donors: An Indian Experience

2021 ◽  
Author(s):  
PVSN Kiran Kumar ◽  
Mithu Banerjee ◽  
Archana Bajpayee ◽  
Saptarishi Mandal ◽  
Prasenjit Mitra ◽  
...  
Keyword(s):  
Igg Antibody ◽  
Clinical Correlates ◽  
Indian Experience

Diagnostic and clinical significance of Crohn’s disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies

2016 ◽  
Vol 54 (2) ◽  
Author(s):  
Polychronis Pavlidis ◽  
Lars Komorowski ◽  
Bianca Teegen ◽  
Christos Liaskos ◽  
Andreas L. Koutsoumpas ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Significance ◽  
Clinical Utility ◽  
Disease Onset ◽  
Pancreatic Tissue ◽  
Colonic Disease ◽  
Igg Antibody ◽  
Clinical Correlates ◽  
Younger Age

AbstractPancreatic autoantibodies (PAB) targeting GP2 and CUZD1 are Crohn’s disease (CrD)-markers. The clinical significance of anti-GP2 antibodies has been assessed, but that of anti-CUZD1 remains elusive. The aim of the study was to assess the clinical utility of anti-CUZD1/anti-GP2 by novel cell-based indirect immunofluorescence (IIF) assays in CrD.A total of 212 CrD and 249 UC patients followed up at a London IBD centre were investigated to simultaneously detect PABs, anti-GP2 and anti-CUZD1 by IIF using primate pancreatic tissue, and HEK293 over-expressing CUZD1 or GP2.Overall, 88 (41.5%) CrDs compared to 26 (10.4%) UCs (p<0.001) tested positive for IgA and/or IgG anti-GP2 and/or anti-CUZD1 antibodies, while ASCA were found in 67.5% CrDs versus 19.2% UCs (p<0.0001); ASCA and/or PAB (anti-GP2 or anti-CUZD1) were detected in 76% CrD versus 34% UC patients. IgG anti-GP2 antibodies were less prevalent in L2 phenotype (p=0.002) and more prevalent in patients with stricturing disease (p=0.0418), even when a higher cut-off (≥1000 RU) was used (p=0.0396). Also, anti-GP2 IgG positive CrD patients had younger age of disease onset. IgA and/or IgG ASCA and anti-GP2 IgG antibody positive CrDs had younger onset of disease (p<0.0001), were more likely to have both ileal and colonic disease (p<0.0001) and had more stricturing (p<0.0001) than seronegative patients. Clinical correlates were not found for anti-CUZD1 positivity.PAB testing increases ASCA’s serological sensitivity for CrD. Anti-GP2 detection, in isolation or in combination with ASCA, stratify CrD patients who phenotypically are characterised by a much younger onset of disease, extensive and stricturing behaviour.

Abstract #278: Insulin Pumps for “Life” vs Insulin Pumps for “Luxury”-the Indian Experience in Type 2 Diabetes

2015 ◽  
Vol 21 ◽  
pp. 64-65
Author(s):  
Jothydev Kesavadev ◽  
Shashank Joshi ◽  
Banshi Saboo ◽  
Pradeep Pillai ◽  
Arun Shankar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Pumps ◽  
Indian Experience

Review of Psychology in a Third World Country: The Indian Experience.

1988 ◽  
Vol 33 (10) ◽  
pp. 924-924
Author(s):  
No authorship indicated
Keyword(s):  
Third World ◽  
World Country ◽  
Third World Country ◽  
Indian Experience

Patterns and clinical correlates of Anxiety Disorder Not Otherwise Specified in youth

2011 ◽  
Author(s):  
Kaitlin P. Gallo ◽  
Priya Korathu-Larson ◽  
Jonathan S. Comer
Keyword(s):  
Anxiety Disorder ◽  
Clinical Correlates ◽  
Not Otherwise Specified

Substance misuse in first episode psychotic patients: sociodemographic, premorbid and clinical correlates. Data from the PICOS-Veneto study

2011 ◽  
Vol 38 (S 01) ◽  
Author(s):  
S Tosato ◽  
R Mazzoncini ◽  
A Lasalvia ◽  
C Bonetto ◽  
M Bertani ◽  
...  
Keyword(s):  
Substance Misuse ◽  
First Episode ◽  
Clinical Correlates

Partial Inhibition of Platelet Aggregation and Fibrinogen Binding by a Murine Monoclonal Antibody to GPIIIa: Requirement for Antibody Bivalency

1994 ◽  
Vol 72 (06) ◽  
pp. 964-972 ◽  
Author(s):  
Jeffery L Kutok ◽  
Barry S Coller
Keyword(s):  
Monoclonal Antibody ◽  
Platelet Aggregation ◽  
Murine Monoclonal Antibody ◽  
Platelet Glycoprotein ◽  
Igg Antibody ◽  
Surface Receptors ◽  
Partial Inhibition ◽  
Fibrinogen Binding ◽  
Igg Binding ◽  
Agonist Concentration

SummaryWe produced a murine monoclonal antibody, 7H2, and localized its epitope to one or more small regions on platelet glycoprotein (GP) Ilia. 7H2-IgG and 7H2-F(ab’)2 completely inhibit platelet aggregation and fibrinogen binding at low agonist concentrations, but only partially inhibit aggregation and fibrinogen binding at high agonist concentrations; 7H2-Fab has no effect on aggregation or fibrinogen binding at any agonist concentration. 7H2-IgG binds to the entire platelet population as judged by flow cytometry. At near saturating concentrations, ∼40,000 7H2-IgG antibody molecules bind per platelet. In contrast, ∼80,000 7H2 Fab molecules bind per platelet, suggesting that 7H2-IgG binding is bivalent. 7H2 was unable to inhibit fibrinogen binding to purified, immobilized GPIIb/IIIa. These data indicate that the bivalent binding of 7H2 to GPIIIa is required for its partial inhibition of fibrinogen binding to platelets, perhaps through dimerization of GPIIb/IIIa surface receptors (or more complex GPIIb/IIIa redistribution triggered by 7H2 binding) resulting in limited accessibility of fibrinogen to its binding site(s).

Sign in / Sign up

Export Citation Format

Share Document